BackEuropean Biotech Acquisition - Units (1 Ord Share Class A & 1/3 War) Overview
European Biotech Acquisition Corp - Units (1 Ord Share Class A & 1/3 War)

European Biotech Acquisition - Units (1 Ord Share Class A & 1/3 War) Return on Equity

Valuation check: EBACU's ROE is 2.89%, above the sector sector average of -4.47%.

Get informed when a big investor buys or sells

+ Follow

ROE

2.89%

Return on Equity

2.89%

Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.

Average ROE (Comparison Companies)

Loading

ROE History

Loading

ROE Comparison

Loading

European Biotech Acquisition - Units (1 Ord Share Class A & 1/3 War) (EBACU) FAQ

As of the most recent data, EBACU shows a ROE of 2.89%. That is above the sector sector average of -4.47%. Scroll down for historical charts and peer comparison views.

The its sector sector average ROE is about -4.47%. European Biotech Acquisition - Units (1 Ord Share Class A & 1/3 War) is at 2.89%, which is higher that average. That is roughly 164.7% above the sector mean. Use the comparison chart on this page to see how EBACU stacks up against individual peers as well.

Check the historical chart to see whether EBACU's ROE is trending up or down. Improvement over multiple periods is generally more meaningful than a single strong quarter. Compare European Biotech Acquisition - Units (1 Ord Share Class A & 1/3 War) with peers to see if the move is company-specific or sector-wide.

Besides this return on equity page, Stockcircle has European Biotech Acquisition - Units (1 Ord Share Class A & 1/3 War)'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect ROE (currently 2.89%) with ownership activity and broader fundamentals.